Should I buy or sell Inventiva stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks .

What is Inventiva's stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for Inventiva's stock. Their IVA share price targets range from $11.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 423.1% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts .

How have IVA shares performed in 2024?

Inventiva's stock was trading at $4.52 at the beginning of the year. Since then, IVA stock has decreased by 28.1% and is now trading at $3.25. View the best growth stocks for 2024 here .

Are investors shorting Inventiva?

Inventiva saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 57,600 shares, a decline of 52.7% from the March 15th total of 121,900 shares. Based on an average trading volume of 39,400 shares, the days-to-cover ratio is currently 1.5 days. View Inventiva's Short Interest .

When did Inventiva IPO?

Inventiva (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free IVA Stock Alerts

$3.19

-0.09 (-2.74%)

(As of 11:47 AM ET)

Compare

Today's Range: $3.19
▼
$3.41
50-Day Range: $3.27
▼
$4.36
52-Week Range: $2.22
▼
$5.05

Volume: 11,349 shs
Average Volume: 37,243 shs
Market Capitalization: $167.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get Inventiva alerts:

Inventiva MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 423.1% Upside
$17.00 Price Target
Short Interest: Healthy
0.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.23) to ($2.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

461st out of 930 stocks

Pharmaceutical Preparations Industry

214th out of 430 stocks

3.5

Analyst's Opinion

Consensus Rating
Inventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Inventiva has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.11% of the outstanding shares of Inventiva have been sold short.
Short Interest Ratio / Days to Cover
Inventiva has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inventiva has recently decreased by 52.75%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inventiva does not currently pay a dividend.
Dividend Growth
Inventiva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVA.

2.7

News and Social Media Coverage

News Sentiment
Inventiva has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Inventiva this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
6 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inventiva insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 19.06% of the stock of Inventiva is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Inventiva are expected to decrease in the coming year, from ($2.23) to ($2.40) per share.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IVA Stock News Headlines

April 9, 2024 | americanbankingnews.com

Canaccord Genuity Group Boosts Inventiva (NASDAQ:IVA) Price Target to $20.00

April 3, 2024 | globenewswire.com

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 1, 2024 | msn.com

Julianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical Trials

April 1, 2024 | finance.yahoo.com

Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)

March 28, 2024 | finanznachrichten.de

INVENTIVA: Inventiva announces the nomination of Andre Turenne as Director

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 28, 2024 | globenewswire.com

Inventiva announces the nomination of Andre Turenne as Director

March 27, 2024 | finanznachrichten.de

INVENTIVA: Inventiva reports its 2023 full-year results

March 27, 2024 | globenewswire.com

Inventiva reports its 2023 full-year results

March 22, 2024 | globenewswire.com

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

March 21, 2024 | markets.businessinsider.com

Promising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH Treatment

March 18, 2024 | markets.businessinsider.com

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

March 18, 2024 | globenewswire.com

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

March 18, 2024 | seekingalpha.com

Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead

March 14, 2024 | bizjournals.com

Shares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatment

March 13, 2024 | globenewswire.com

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

March 8, 2024 | markets.businessinsider.com

Inventiva’s Clinical Progress and Financial Valuation Reinforce Buy Rating

March 8, 2024 | markets.businessinsider.com

Inventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising Outlook

March 7, 2024 | globenewswire.com

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

February 17, 2024 | markets.businessinsider.com

Buy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety Record

February 16, 2024 | msn.com

Inventiva halt recruitment for Phase III NASH trial following adverse event

February 16, 2024 | marketwatch.com

Inventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Event

February 15, 2024 | finanznachrichten.de

INVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3

February 15, 2024 | finance.yahoo.com

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

See More Headlines

Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IVA
CUSIP: N/A
CIK: 1756594
Web: www.inventivapharma.com
Phone: 33-3-80-44-75-00
Fax: N/A
Employees: 117
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $25.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +418.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.96
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: $18.91 million
Price / Sales: 9.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.67) per share
Price / Book: -4.90

Miscellaneous

Outstanding Shares: 52,480,000
Free Float: 35,684,000
Market Cap: $172.13 million
Optionable: Not Optionable
Beta: 0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Frederic Cren (Age 58)
Co-Founder, CEO & Chairman
Comp: $547.9k
Dr. Pierre Broqua Ph.D. (Age 62)
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Comp: $410.96k
Mr. Jean Volatier (Age 59)
Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer
Mr. Eric Duranson L.L.M. (Age 50)
General Counsel
Ms. Nathalie Harroy (Age 57)
Head of Human Resources
Dr. Michael Cooreman (Age 66)
Chief Medical Officer
Pascaline Clerc Ph.D.
Executive VP of Strategy & Corporate Affairs

Key Competitors

View All Competitors

IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares.
View IVA analyst ratings or view top-rated stocks.
What is Inventiva's stock price target for 2024?: 8 Wall Street research analysts have issued 1-year price objectives for Inventiva's stock. Their IVA share price targets range from $11.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 423.1% from the stock's current price.
View analysts price targets for IVA or view top-rated stocks among Wall Street analysts.
How have IVA shares performed in 2024?: Inventiva's stock was trading at $4.52 at the beginning of the year. Since then, IVA stock has decreased by 28.1% and is now trading at $3.25.
View the best growth stocks for 2024 here.
Are investors shorting Inventiva?: Inventiva saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 57,600 shares, a decline of 52.7% from the March 15th total of 121,900 shares. Based on an average trading volume of 39,400 shares, the days-to-cover ratio is currently 1.5 days.
View Inventiva's Short Interest.

When did Inventiva IPO?: Inventiva (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.
How do I buy shares of Inventiva?: Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inventiva (IVA) Stock Price, News & Analysis

Inventiva MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inventiva Stock (NASDAQ:IVA)

IVA Stock Price History

IVA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

IVA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™